Gilead Sciences Inc.
Gilead Sciences (GILD) is a large US biopharmaceutical company best known for antiviral medicines, including treatments for HIV and hepatitis, and therapies for COVID-19 and certain cancers. With a market capitalisation of about $153.96 billion, Gilead blends steady cash-generating legacy products with newer growth avenues such as cell therapies and oncology after strategic acquisitions. Investors should note the company’s reliance on a handful of high‑revenue drugs, exposure to patent expiries and pricing pressures, and the binary nature of clinical trial outcomes that can materially affect share price. Gilead pays a dividend and typically generates strong free cash flow, which can appeal to income-focused investors, but returns are not guaranteed. This summary is for educational purposes only and not personalised investment advice; consider your risk tolerance and time horizon, and consult a regulated adviser before making investment decisions.
Why It's Moving
GILD Faces Analyst Warnings of 9% Downside Ahead of Pivotal Q4 Earnings Reveal
- Implied volatility spikes in Feb. 2026 $150 put options, reflecting trader expectations of significant downside moves and heightened uncertainty.
- Q4 earnings due February 10 with consensus at $1.90 per share, up from $1.85 over the last 60 days, putting pressure on Gilead to deliver amid HIV and oncology focus.
- Analyst price targets cluster below recent highs around $152, implying roughly 9% risk to the downside despite mostly Buy ratings from major firms.
GILD Faces Analyst Warnings of 9% Downside Ahead of Pivotal Q4 Earnings Reveal
- Implied volatility spikes in Feb. 2026 $150 put options, reflecting trader expectations of significant downside moves and heightened uncertainty.
- Q4 earnings due February 10 with consensus at $1.90 per share, up from $1.85 over the last 60 days, putting pressure on Gilead to deliver amid HIV and oncology focus.
- Analyst price targets cluster below recent highs around $152, implying roughly 9% risk to the downside despite mostly Buy ratings from major firms.
When is the next earnings date for Gilead Sciences Inc. (GILD)?
Gilead Sciences (GILD) is scheduled to release its next earnings report for the fourth quarter and full year 2025 on Tuesday, February 10, 2026. This follows their most recent Q3 2025 earnings reported on October 30, 2025. Investors should anticipate the announcement after market close, with a conference call to discuss results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Gilead's stock with a target price of $132.55, indicating potential growth.
Financial Health
Gilead Sciences is generating strong profits and cash flow, indicating good overall financial health.
Dividend
Gilead Sciences offers a dividend yield of 2.06%, which is moderate for income-focused investors. If you invested $1000 you would be paid $31.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GILD
Pharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: June 18, 2025
Explore BasketCompanies That Give Back
Channel your investments toward companies that make philanthropy a priority. These stocks have been carefully selected by our analysts for their commitment to giving back while building sustainable businesses that could deliver long-term value to investors.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketTop Stocks for Recessions
These carefully selected stocks have shown remarkable resilience during economic downturns. Our team of professional analysts has identified companies that maintain stability when markets get shaky, giving you options for weathering financial storms.
Published: May 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Antiviral Franchise
Strong HIV and hepatitis drugs deliver predictable revenues, though sales can be affected by competition and patent expiries.
Oncology & Cell Therapy
Newer programmes and acquisitions expand growth potential, but clinical and regulatory outcomes can be binary and affect valuations.
Cash Flow & Dividend
Solid cash generation supports a dividend and buybacks, yet income investors should remember dividends can change and are not guaranteed.
Compare Gilead Sciences with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
